Takeda Ventures, Inc. focuses its investments on high-caliber, early-stage, preclinical therapeutic and platform-based companies globally that complement Takeda's pipeline in areas like Oncology, Rare Genetics & Hematology, Neuroscience, and Gastrointestinal and Inflammation. Its strategy is to create strategic growth opportunities for Takeda by building, managing, and investing in innovative life science companies and supporting therapeutic innovation.
50% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Average disclosed round size is $49.1M (across 11 rounds with reported amounts).
Portfolio
12
Fund Size
$500M
Top Stage
Series A
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
12 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Accipiter Biosciences | Seed | $12.7M | Nov 2025 |
| IIntegra Therapeutics | Pre-Seed | $10.7M | Sep 2025 |
 Oshi Health | Series C | $60M | Jan 2025 |
 Enzyre | Series A | $12M | Nov 2022 |
 Koneksa | Series C | $45M | Feb 2022 |
 aptihealth | Series B | $50M | Nov 2021 |
 Tele911 Inc. | Seed | — | Nov 2021 |
 BridGene Biosciences | Series A | $12M | May 2021 |
 StrideBio, Inc. | Series B | $81.5M | Mar 2021 |
 Aspen RxHealth | Series B | $23M | Jan 2021 |
 Amwell | Series C | $194M | May 2020 |
 OrphoMed | Series A | $39M | May 2017 |
Top Co-Investors
Alexandria Venture Investments2 shared
McKesson Ventures2 shared
Bessemer Venture Partners2 shared
Flare Capital Partners2 shared
Flying Fish1 shared
Columbus Venture Partners1 shared
Cercano Management1 shared
Washington Research Foundation1 shared
Argonautic Ventures1 shared
Merck Global Health Innovation Fund1 shared
Novartis Venture Fund1 shared
Spring Mountain Capital1 shared
Humana1 shared
Northpond Ventures1 shared
Pontifax1 shared
CaaS Capital1 shared
UCB1 shared
NEA (New Enterprise Associates)1 shared
Last updated: 16 April 2026